Financial Performance - For the nine months ended September 30, 2024, the Company generated $15.21 million in commission from the Distribution Business[298]. - Total revenues decreased by 58.81% from $13,207,000 in 2024 to $5,440,000 in 2025[315]. - Distribution Business revenue fell by 60.42%, from $11,876,000 in 2024 to $4,701,000 in 2025, primarily due to economic recession and outward migration in Hong Kong[317]. - Total revenues for the nine months ended September 30, 2024, were US$18.017 million, a decrease of US$23.634 million, or 56.74%, compared to the same period in 2023[340]. - The Distribution Business generated US$15.211 million in revenue for the nine months ended September 30, 2024, down US$22.358 million, or 59.51%, from US$37.569 million in 2023[341]. - For the nine months ended September 30, 2025, the company reported a net loss of approximately US$28.8 million, with an accumulated deficit of approximately US$94.4 million[383]. - Net cash used in operating activities was US$20.7 million for the nine months ended September 30, 2025, compared to US$33.4 million for the same period in 2024[375]. Operating Expenses - Total operating expenses decreased by 36.36% from $24,550,000 in 2024 to $15,623,000 in 2025[315]. - Commission expense dropped by 78.31%, from $8,916,000 in 2024 to $1,934,000 in 2025[322]. - Personnel and benefit expenses decreased by 45.44% from $6,446,000 in 2024 to $3,517,000 in 2025[327]. - Legal and professional fees decreased by 19.46% from $3,531,000 in 2024 to $2,844,000 in 2025[329]. - Loss from operations decreased by US$1.2 million, or 10.23%, for the three months ended September 30, 2024, primarily due to a decrease in operating expenses of US$8.9 million[333]. - Loss from operations decreased by US$10.5 million, or 29.01%, for the nine months ended September 30, 2024, attributed to a significant decrease in operating expenses[356]. Cash Flow and Financing - Net cash provided by financing activities for the nine months ended September 30, 2025, was US$18.3 million, mainly due to advances from the holding company of US$15.6 million and proceeds from convertible promissory notes of US$23.4 million[380]. - The company intends to raise additional capital through various debt and equity offerings, but there is no assurance that these funds will be available on acceptable terms[386]. - The management estimates that currently available cash will not be sufficient to meet the company's planned obligations for the next 12 months[382]. - The company expects to continue operating losses as it invests in business growth, with cash and equivalents projected to be insufficient for operations for at least the next 12 months[369]. Business Segments - The Distribution Business includes a leading financial advisor business with approximately 562 financial advisors organized into 10 sales teams as of September 30, 2024[292]. - The Platform Business offers over 1,800 financial products, including 1,183 insurance products from 80 providers and 1,141 asset management products from 53 fund houses[304]. - The Fintech Business includes investments in Tandem Money Limited, CurrencyFair Limited, Oscar Health Inc., and Goxip Inc., with a carrying amount of $17.75 million for Tandem Money as of September 30, 2025[307]. - The Company holds a 4% equity stake in HCMPS, which operates a network of over 800 doctors and provides healthcare schemes for more than 500 corporate clients[310][311]. - JFA, under HCMPS, aims to transform into the best medical care institution in Asia by 2025, focusing on technology and data analytics to enhance patient care[314]. Compliance and Regulatory - The Company received an exception period from Nasdaq to comply with listing requirements, with deadlines set for December 24, 2025, February 27, 2026, and September 30, 2026[288]. - Nasdaq granted the company an additional 180 days until September 16, 2024, to regain compliance, which was achieved on May 3, 2024[388]. - The company has not engaged in any off-balance sheet financial arrangements that could materially affect its financial condition[389].
Triller Group Inc.(ILLR) - 2025 Q3 - Quarterly Report